CD44 and neoplasm: In addition, the frequency of effector memory T cell (TEM) (CD3+ CD8+ CD44+ CD62L−) in mU@OMVs treated mice increased by 29.93% compared with that of PBS control, demonstrating that mU@OMVs could induce potent long-term immune memory effects to prevent tumor recurrence.